Cargando…

New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations

SIMPLE SUMMARY: This manuscript focuses on improving the treatment of non-small cell lung cancer, with actionable gene alterations. The aim is to understand how the treatment with Tyrosine Kinase Inhibitors (TKIs) can be used and improved. Newer generations of TKIs have better results in controlling...

Descripción completa

Detalles Bibliográficos
Autores principales:	Attili, Ilaria, Corvaja, Carla, Spitaleri, Gianluca, Del Signore, Ester, Trillo Aliaga, Pamela, Passaro, Antonio, de Marinis, Filippo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605462/ https://www.ncbi.nlm.nih.gov/pubmed/37894445 http://dx.doi.org/10.3390/cancers15205079

Ejemplares similares

MET in Non-Small-Cell Lung Cancer (NSCLC): Cross ‘a Long and Winding Road’ Looking for a Target
por: Spitaleri, Gianluca, et al.
Publicado: (2023)

Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?
por: Spitaleri, Gianluca, et al.
Publicado: (2023)

Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50%
por: Attili, Ilaria, et al.
Publicado: (2022)

Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way
por: Attili, Ilaria, et al.
Publicado: (2020)

Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence
por: Attili, Ilaria, et al.
Publicado: (2022)

Safety of mRNA-COVID-19 Vaccines in Patients With Thoracic Cancers
por: Spitaleri, G., et al.
Publicado: (2023)

Fears and Perception of the Impact of COVID-19 on Patients With Lung Cancer: A Mono-Institutional Survey
por: Catania, Chiara, et al.
Publicado: (2020)

Results of Multilevel Containment Measures to Better Protect Lung Cancer Patients From COVID-19: The IEO Model
por: de Marinis, Filippo, et al.
Publicado: (2020)

erbB in NSCLC as a molecular target: current evidences and future directions
por: Del Re, Marzia, et al.
Publicado: (2020)

Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations
por: Passaro, Antonio, et al.
Publicado: (2021)

Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features
por: Passaro, Antonio, et al.
Publicado: (2021)

Role of Radiosurgery and Stereotactic Ablative Radiotherapy for Oligometastatic Non-Oncogene Addicted NSCLC
por: Badellino, Serena, et al.
Publicado: (2022)

ESMO20 YO for YO: highlights on oncogene-addicted NSCLC
por: Lim, K.H.J., et al.
Publicado: (2020)

Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice
por: Passaro, Antonio, et al.
Publicado: (2016)

Use of liquid biopsy in monitoring therapeutic resistance in EGFR oncogene addicted NSCLC
por: Iacovino, Marialucia, et al.
Publicado: (2020)

Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion
por: Gridelli, Cesare, et al.
Publicado: (2023)

STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer
por: Attili, Ilaria, et al.
Publicado: (2018)

Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC
por: Gal, Omer, et al.
Publicado: (2020)

Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options
por: Petrella, Francesco, et al.
Publicado: (2023)

Testing for COVID-19 in lung cancer patients
por: Passaro, A., et al.
Publicado: (2020)

Immunotherapy in NSCLC Patients with Brain Metastases
por: Buriolla, Silvia, et al.
Publicado: (2022)

Oncogene addiction and immune escape: friends or foes?
por: Abdayem, Pamela, et al.
Publicado: (2020)

Oncogene addiction and radiation oncology: effect of radiotherapy with photons and carbon ions in ALK-EML4 translocated NSCLC
por: Dai, Ying, et al.
Publicado: (2018)

Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC
por: Ma, Weijie, et al.
Publicado: (2021)

Efficacy of Incremental Next-Generation ALK Inhibitor Treatment in Oncogene-Addicted, ALK-Positive, TP53-Mutant NSCLC
por: Urbán, László, et al.
Publicado: (2020)

Targeting of non-oncogene addiction
por: Igea, Ana, et al.
Publicado: (2015)

Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy
por: Del Re, Marzia, et al.
Publicado: (2019)

Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report
por: Enrico, Diego, et al.
Publicado: (2020)

Oncogenic mutation or overexpression of oncogenic KRAS or BRAF is not sufficient to confer oncogene addiction
por: Ito, Reina E., et al.
Publicado: (2021)

Incorporating atezolizumab in the adjuvant setting of non-small cell lung cancer: key discussion points from an expert multidisciplinary panel by Italian Association of Thoracic Oncology
por: de Marinis, Filippo, et al.
Publicado: (2022)

New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond
por: Gori, Bruno, et al.
Publicado: (2011)

Editorial: Immunotherapy for NSCLC with oncogenic driver variants
por: Du, Yijia, et al.
Publicado: (2022)

Oncogene addiction: resetting the safety switch?
por: Li, Yulin, et al.
Publicado: (2014)

BIM-mediated apoptosis and oncogene addiction
por: Li, Yulin, et al.
Publicado: (2016)

Rhabdomyosarcomas are oncogene addicted to the activation of AVIL
por: Xie, Zhongqiu, et al.
Publicado: (2022)

Drugging the addict: non‐oncogene addiction as a target for cancer therapy
por: Nagel, Remco, et al.
Publicado: (2016)

Rescue Surgery after Immunotherapy/Tyrosine Kinase Inhibitors for Initially Unresectable Lung Cancer
por: Galetta, Domenico, et al.
Publicado: (2022)

circ_0005962 functions as an oncogene to aggravate NSCLC progression
por: Zhang, Zhihong, et al.
Publicado: (2021)

Overcoming MET-mediated resistance in oncogene-driven NSCLC
por: Reischmann, Nadine, et al.
Publicado: (2023)

Oncogene addiction to c-MYC in myeloma cells
por: Holien, Toril, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ni1t4v386t1ij0n6u5a1642j17